Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

Overview of attention for article published in New England Journal of Medicine, November 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 32 news outlets
blogs: 11 blogs
policy: 5 policy sources
twitter: 125 X users
patent: 32 patents

facebook: 12 Facebook pages
wikipedia: 11 Wikipedia pages
reddit: 3 Redditors
f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 1781 Mendeley

So far, Altmetric has seen 16 posts from 11 blogs.

The Lancet Summit: presymptomatic prevention and treatment of neurodegenerative diseases

CureFFI.org, 16 Dec 2021

The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases was held virtually December 14 - 16…

Conquering the next mountain in spinal muscular atrophy

Neuro Central, 13 Oct 2021

[popup title="Important information"]The following feature is intended for healthcare professionals only. Please tick the box…

Gene Replacement Therapy Shows Benefit in Symptomatic Spinal Muscular Atrophy 1

Physician's Weekly, 06 Oct 2021

European study included infants with more advanced…

SMA: Disease-Modifying Therapies Change the Course of Patients’ Lives

Physician's Weekly, 19 Jun 2020

Two drugs now approved in the U.S., and a third is under…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 12 additional blog posts.